Topiramate Tablet, Film Coated
Product Images NDC 68071-3660

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 68071-3660). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (0ed6c856 4d95 4aeb B925 15346555a2ab 565 2)

FDA Label Image

Pdp (68071 3660 3)

Pdp (68071 3660 3)
Topiramate 25 mg film-coated tablets label from NuCare Pharmaceuticals, Inc. The label indicates 30 tablets per package. Tablets are described as round, biconvex, light yellow with 'U' debossed on one side and '115' on the other. Manufactured by Unichem Laboratories Ltd., Ghazizabad, India. Contains dosage and storage instructions along with NDC code 68071-3660-3.*
FDA Label Image

Image (9df497de Be9f 4244 A769 A72a0e64dc42 01)

Image (9df497de Be9f 4244 A769 A72a0e64dc42 01)
Chemical structure of topiramate, showing the molecular arrangement of atoms including sulfonamide and multiple methyl groups.*
FDA Label Image

Image (9df497de Be9f 4244 A769 A72a0e64dc42 02)

Image (9df497de Be9f 4244 A769 A72a0e64dc42 02)
A line graph showing cumulative rates for time to first seizure over a period of 500 days, comparing topiramate dosages of 50 mg/day and 400 mg/day. The x-axis represents time in days, and the y-axis represents cumulative rates. The graph includes statistical notation (p = 0.0002) indicating significance between the two dosage groups.*
FDA Label Image

Image (9df497de Be9f 4244 A769 A72a0e64dc42 03)

Image (9df497de Be9f 4244 A769 A72a0e64dc42 03)
A bar graph comparing changes from baseline to double-blind phase in average monthly migraine period rate across different doses of topiramate (50 mg/day, 100 mg/day, 200 mg/day) versus placebo. Data are provided for two studies, with statistical significance indicated by asterisks for higher doses showing reduced migraine rates compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.